Background
==========

Vulnerability to substance dependence is a complex trait with strong genetic influences that are well documented by data from family, adoption and twin studies \[[@B1]-[@B4]\]. Twin studies support the view that much of the heritable influence on vulnerability to dependence on addictive substances from different pharmacological classes (*eg*nicotine and stimulants) is shared \[[@B2],[@B3],[@B5]\]. Combined data from linkage and genome wide association (GWA) datasets \[[@B6]-[@B11]\] suggest that most of the genetics of vulnerability to dependence on addictive substances is likely to be polygenic, arising from variants in genes whose influences on vulnerability, taken one at a time, are relatively modest. Substance-dependent individuals also differ from control individuals in personality, cognitive domains and co-occurrence of psychiatric diagnoses \[[@B1],[@B12]\] (reviewed in \[[@B13]\]).

GWA approaches of increasing sophistication have been developed and used to identify the specific genes and genomic variants that predispose to vulnerability to substance dependence. For example, we have assembled a group of research volunteers from the Molecular Neurobiology Branch of the NIH (NIDA) intramural research program in Baltimore between 1990 and 2008 (\"MNB\"). We have compared allele frequencies at *ca*1500, 10,000, 100,000, 500,000 and then 1,000,000 SNP markers in increasing numbers of substance dependent *vs*control individuals from this growing sample, including 680 substance dependent or control individuals with self reported European ancestries \[[@B6]-[@B9],[@B11]\], (Drgon et al, submitted).

There is the theoretical concern that this MNB sample, and many of the other samples collected for studies of genetics of dependence on addictive substances, might be biased based on the requirement that subjects were ascertained when they volunteered for research. It is conceivable that \"volunteering\" might interact with heritable features of personality, cognitive, psychiatric and/or other features by which substance dependent individuals might differ from controls \[[@B1],[@B12]-[@B25]\]. GWA findings in such research volunteer samples would then conceivably provide a distorted representation of findings that would otherwise be made in members of the community.

The Baltimore site of the Epidemiological Catchment Area (ECA) Study provides a good comparison group to probe such potential confounding features \[[@B24],[@B26]\]. This study initially assembled a probability sample of individuals who represented the East Baltimore population, including many of the census tracts in which MNB research volunteers reported their home residences. ECA investigators followed substantial portions of these individuals, interviewing them four times and sampling DNA from most of the 1071 individuals from the initial sample who were interviewed in 2004--05 (*see below*). The repeated assessment of these individuals provides confident assessment of dependence-related phenotypes that include DSM diagnoses of substance abuse and dependence and Fagerstrom Test for Nicotine Dependence (FTND) diagnoses of nicotine dependence.

We thus now report data that confirms the overlapping areas of Baltimore from which ECA and MNB subjects were sampled. We report genome wide association studies for substance dependence phenotypes for Baltimore ECA subjects. We compare these genome wide association results with those from ethnically-matched MNB research volunteers who were recruited from many of the same areas. We discuss the significance of the substantially-overlapping data that we report, as well as the limitations of the samples and datasets. These data document large molecular genetic overlaps between probability-sample and research volunteer samples for substance dependence.

Methods
=======

ECA Sample
----------

Subjects from the Baltimore (Eastern Baltimore Mental Health Survey) site for the Epidemiological Catchment Area Program (ECA) were ascertained as a probability sample of individuals in dwelling units within census tracts near the Johns Hopkins Medical Institutions and initially interviewed in 1981 \[[@B24],[@B26]\]. Subsets of these individuals were interviewed in 1982, 1993--96 and 2004--5. Diagnoses came from the Diagnostic Interview Schedule (DIS), a self-report instrument \[[@B27]\] whose validity and reliability has been documented in this sample \[27a\]. Smoking was also described using the Fagerstrom Test for Nicotine Dependence (FTND) \[[@B28]-[@B30]\]. Although many of the individuals who were \> 65 in 1981 had died by the 2004--05 follow-up, self-report survey data was collected from 662 European-American respondents (63% female) during this follow-up. This subset provided good representation of the composition of the portion of the original Baltimore ECA cohort that was of this race/ethnicity. Blood for DNA extraction and for lymphocyte immortalization was obtained from 74% of these individuals, who did not differ from subjects from whom DNA was not obtained in any obvious feature that related to substance dependence \[30a\].

Individuals who were dependent on an abused substance were identified by DSM criteria, except for nicotine dependence which was based on FTND criteria. Eighty substance dependent individuals were identified. These individuals were matched for gender and age to eighty control individuals. These control individuals were East Baltimore ECA participants who never used any illegal drugs more then 5 times in their lives, were not dependent on any drug or alcohol, drank less than one drink per day (waves 3 and 4) drank less than 5 drinks/week (waves 1 and 2) and had FTND scores \< 7. Generation and analyses of these data were approved by the Johns Hopkins Bloomberg School of Public Health IRB and exempt protocols for pooled genotyping approved by the NIH Office of Human Research Subject Protection.

Comparison research volunteer sample
------------------------------------

Data from these European-American ECA subjects was compared to data from European-American MNB research volunteers who provided informed consents, ethnicity data, drug use histories and DSMIII-R or IV diagnoses as previously described \[[@B6],[@B31],[@B32]\]. DNA in 34 pools sampled 400 \"abusers\" with heavy lifetime use of illegal substances and, for virtually all, DSMIII-R/IV dependence on at least one illegal abused substance and 280 \"controls\" who reported no significant lifetime use of any addictive substance. Generation and analyses of these data were approved by the NIH IRP (NIDA) IRB (protocol \#148) and exempt protocols for pooled genotyping approved by the NIH Office of Human Research Subject Protection.

DNA preparation and assessment of allelic frequencies
-----------------------------------------------------

DNA was prepared from blood (MNB and some ECA subjects) or cell lines (most ECA subjects) \[[@B6],[@B31],[@B32]\] and carefully quantitated. DNAs from groups of 20 individuals of the same phenotype were combined. Hybridization probes were prepared with precautions to avoid contamination, as described (Affymetrix assays 500 k \[[@B9],[@B11],[@B33],[@B34]\]). 150 ng of pooled DNA was digested using *Sty*I or *Nsp*I, ligated to appropriate adaptors and amplified using a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA) with 3 min 94°C, 30 cycles of 30 sec 94°C, 45 sec 60°C, 15 sec at 68°C and a final 7 min 68°C extension. PCR products were purified (MinEluteTM 96 UF kits, Qiagen, Valencia, CA) and quantitated. Forty μg of PCR product was digested for 35 min at 37°C with 0.04 unit/μl DNase I to produce 30--100 bp fragments which were end-labeled using terminal deoxynucleotidyl transferase and biotinylated dideoxynucleotides and hybridized to the appropriate 500 k array (*Sty I*or *Nsp I*arrays) (Mendel array sets, Affymetrix). Arrays were stained and washed as described (Affymetrix Genechip Mapping Assay Manual) using immunopure strepavidin (Pierce, Milwaukee, WI), biotinylated antistreptavidin antibody (Vector Labs, Burlingame, CA) and R-phycoerythrin strepavidin (Molecular Probes, Eugene, OR). Arrays were scanned and fluorescence intensities quantitated using an Affymetrix array scanner as described \[[@B9],[@B11],[@B33],[@B34]\].

Chromosomal positions for each SNP were sought using NCBI (Build 36.1) and NETAFFYX (Affymetrix) data. Allele frequencies for each SNP in each DNA pool were assessed based on hybridization intensity signals from four arrays, allowing assessment of hybridization to the 12 \"perfect match\" cells on each array that are complementary to the PCR products from alleles \"A\" and \"B\" for each diallelic SNP on sense and antisense strands. We eliminated: i) SNPs on sex chromosomes and iii) SNPs whose chromosomal positions could not be adequately determined.

Each array was analyzed as described \[[@B9],[@B11],[@B33],[@B34]\], with background values subtracted, normalization to the highest values noted on the array, averaging of the hybridization intensities from the array cells that corresponded to the perfect match \"A\" and \"B\" cells, calculation of \"A/B ratios\" by dividing average normalized A values by average normalized B values, arctangent transformations to aid combination of data from arrays hybridized and scanned on different days, and determination of the average arctangent value for each SNP from the 4 replicate arrays. A \"t\" statistic for the differences between abusers and controls was generated as described \[[@B9],[@B11],[@B33],[@B34]\] for each SNP. We focused on SNPs that displayed t statistics with p \< 0.05 for abuser/control differences. We sought evidence for clustering of these SNPs by focusing on chromosomal regions in which at least three of these outlier SNPs, assessed by at least two array types, lay within 25 Kb of each other. We term these clustered, nominally-positive SNPs \"clustered positive SNPs\", and focus our analyses on regions in which they lie.

To confirm the SNPs within the positive clusters from the current dataset, we sought convergence between data from these clustered nominally-positive SNPs and clustered nominally-positive SNPs, determined in the same way, from 1 M SNP genome wide association studies of the MNB samples (Drgon et al, submitted). To provide insights into some of the genes likely to harbor variants that contribute to individual differences in vulnerability to substance dependence, we sought candidate genes that were identified by overlapping clusters of positive SNPs from each of these samples.

We compare observed results to those expected by chance using Monte Carlo simulation trials, as described \[[@B9],[@B11],[@B33],[@B34]\]. For each trial, a randomly-selected set of SNPs from the current dataset was assessed to see if it provided results equal to or greater than the results that we actually observed. The number of trials for which the randomly-selected SNPs displayed (at least) the same features displayed by the observed results was then tallied to generate an empirical p value. These simulations thus correct for the number of repeated comparisons made in these analyses, an important consideration in evaluating these GWA datasets. We thus focus on genes which display convergence between nominally-significant results obtained from the two dependence *vs*control samples. We report Monte Carlo probabilities for the observed convergence of clustered nominally positive SNPs within each gene, using simulations that correct for the number of repeated comparisons.

To assess the power of our current approach, we use current sample sizes and standard deviations, the program PS v2.1.31 \[[@B35],[@B36]\] and α = 0.05. To provide controls for the possibilities that abuser-control differences observed herein were due to a) occult ethnic/racial allele frequency differences or b) noisy assays, we assessed the overlap between the results obtained here and the SNPs that displayed the largest a) allele frequency differences between African-American *vs*European-American control individuals and b) the largest assay \"noise\".

We have compared the patterns of human brain expression for the genes identified herein to those identified using a novel tool based on the distribution of expressed sequence tags (ESTs) contained in an annotated set of brain cDNA libraries (CYL, GRU et al, *in preparation*). Briefly, we identified 846 human cDNA libraries with cDNAs represented in dbEST. These libraries were constructed from regions of brains that appeared to display modest or no pathology. We based the analyses on two sets of criteria: 1) all entries in these libraries and 2) \"more reliable\" entries that display i) correct genomic orientation and either ii a) evidence for polyA tail or ii b) spliced structure (CYL, GRU et al, *in preparation*). For each brain region, we assessed the *p*-value for over-representation of expression of the dependence-associated genes using hypergeometric distribution tests with false discovery rate (FDR) corrections. *Q*-values \< 0.05 were considered statistically significant.

Results
=======

We assessed the extent to which the ECA and NIDA research volunteers came from similar Baltimore neighborhoods by comparing the distributions of available zip codes from these samples. As noted in Figure [1](#F1){ref-type="fig"}, there was substantial overlap between these zip code distributions, providing impetus for the comparative molecular genetic studies described below.

![**Substantial overlaps of the zip codes in which subjects reported their residences.** Fractional distributions (*X axis*) of zip codes (*Y axis*) in which ECA (*solid blue bars*) or MNB (*dotted purple bars*) subjects reported their residence. Areas from which NIDA and ECA recruitment efforts were dissimilar include 21214; Lauraville and surrounding areas and 21222, Dundalk and surrounding areas. Zip codes from which fewer than 3 individuals were recruited are not indicated.](1471-2350-9-113-1){#F1}

We then assessed allele frequencies in multiple pools of DNA from substance dependent and control ECA individuals. There was modest variability among replicate arrays that assessed the same pool (standard error of the mean (SEM) 0.032) and among the different pools that assessed the same phenotype (SEM 0.033). These samples and these estimates of variance thus provided 0.9, 0.74, 0.46 and 0.21 power to detect allele frequency differences of 12.5, 10, 7.5 and 5%, respectively.

28,137 SNPs displayed \"nominally positive\" t values with p \< 0.05 in these ECA samples. 7,620 of these nominally positive SNPs fell into 1660 clusters of at least 3 SNPs that came from both array types were separated from adjacent nominally-positive SNPs by less than 25,000 basepairs. Monte Carlo simulations reveal p \< 0.00001 for this degree of clustering.

One hundred seventy two genes are identified by both 1) clusters of nominally-positive SNPs from the ECA samples and 2) overlapping clusters of nominally positive SNPs from MNB samples. We list the 126 of these genes whose nominal Monte Carlo p values are \< 0.05 in Table [1](#T1){ref-type="table"}. This number of genes is never identified by chance in both samples by any of 10,000 Monte Carlo simulation trials (thus, p \< 0.0001). There is also overlap, to extents greater than expected by chance, with the clusters of SNPs whose allele frequencies distinguish MNB African-American polysubstance abusers from controls (p \< 0.0001) \[[@B9]\], Japanese methamphetamine abusers from controls (p \< 0.0001) \[[@B11]\], Taiwanese methamphetamine abusers from controls (p \< 0.0007) \[[@B11]\] and more-frequently nicotine dependent smokers of European ancestry from less-frequently nicotine dependent smokers (p \< 0.0001) \[[@B10]\].

###### 

Genes that contain overlapping clusters of nominally positive SNPs in both ECA and European-American MNB research volunteer samples that display nominal p \< 0.05.

                                                                                        ***Clust SNPs***         
  ------------- ---- ------------- ---------------------------------------------------- ------------------ ----- --------
  A2BP1         16   6,009,133     ataxin 2-binding protein 1                           16                 42    0.0038
  ACCN1         17   28,364,218    neuronal amiloride-sens cation chan 1                5                  5     0.0240
  ADARB2        10   1,218,073     RNA spec A deaminase B2                              4                  8     0.0420
  ADCY2         5    7,449,345     adenylate cyclase 2                                  7                  6     0.0210
  AGBL4         1    48,822,129    ATP/GTP binding protein-like 4                       3                  8     0.0400
  AK5           1    77,520,330    adenylate kinase 5                                   10                 4     0.0090
  AKAP6         14   31,868,274    A kinase anchoring protein 6                         3                  15    0.0210
  ALK           2    29,269,144    anaplastic lymphoma kinase (Ki-1)                    6                  10    0.0470
  ANKFN1        17   51,585,835    ankyrin-rep Fn III dom cont 1                        3                  14    0.0130
  ATXN1         6    16,407,322    ataxin 1                                             3                  17    0.0120
  C18orf1       18   13,208,795    chromosome 18 open reading frame 1                   4                  6     0.0440
  C3orf21       3    196,270,302   chromosome 3 open reading frame 21                   4                  4     0.0380
  C8A           1    57,093,065    complement component 8 α polypep                     3                  7     0.0180
  C9orf88       9    129,307,439   Chr 9 open reading frame 88                          4                  4     0.0220
  CABIN1        22   22,737,765    calcineurin binding protein 1                        4                  4     0.0220
  CACNA2D3      3    54,131,733    voltage det Ca chan α2/δ3 subunit                    12                 18    0.0091
  CCBE1         18   55,252,124    collagen and calcium binding EGF domains 1           7                  10    0.0090
  CCDC63        12   109,769,194   coiled-coil domain containing 63                     3                  4     0.0290
  CD180         5    66,513,872    CD180 molecule                                       5                  5     0.0051
  CDH13         16   81,218,079    cadherin 13                                          18                 65    0.0019
  CDH23         10   72,826,697    cadherin-like 23                                     7                  4     0.0380
  CGNL1         15   55,455,997    cingulin-like 1                                      3                  11    0.0040
  CHL1          3    213,650       close homolog of L1                                  3                  12    0.0103
  CHST11        12   103,370,614   chondroitin 4 sulfotransferase 11                    4                  4     0.0470
  CIT           12   118,607,981   citron rho-interacting, serine/threonine kinase 21   5                  6     0.0160
  CNTN5         11   98,397,081    contactin 5                                          11                 10    0.0390
  CNTNAP2       7    145,444,386   contactin associated protein-like 2                  22                 9     0.0380
  CPVL          7    29,001,772    carboxypeptidase vitellogenic-like                   4                  4     0.0290
  CRYL1         13   19,875,810    crystalline λ1                                       4                  5     0.0170
  CSMD1         8    2,782,789     CUB and Sushi multiple domains 1                     29                 137   0.0014
  CUGBP2        10   11,087,290    CUG triplet repeat RNA bind prot 2                   16                 4     0.0031
  DAB1          1    57,236,167    disabled homolog 1                                   4                  24    0.0140
  DLC1          8    12,985,243    deleted in liver cancer 1                            13                 9     0.0059
  DNAPTP6       2    200,879,041   DNA polymerase-transactivated protein 6              8                  4     0.0140
  DOCK2         5    168,996,871   dedicator of cytokinesis 2                           3                  7     0.0490
  DPP6          7    154,060,464   dipeptidyl-peptidase 6                               6                  4     0.0250
  EDNRA         4    148,621,575   endothelin receptor type A                           3                  4     0.0280
  EFCAB4B       12   3,627,370     EF-hand calcium binding domain 4B                    3                  6     0.0165
  EPHB1         3    135,996,950   EPH receptor B1                                      13                 5     0.0090
  ESRRG         1    214,743,211   estrogen-related receptor γ                          3                  14    0.0210
  EVI1          3    170,285,244   ecotropic viral integration site 1                   3                  12    0.0047
  F5            1    167,750,033   coagulation factor V                                 4                  11    0.0049
  FAM13A1       4    89,866,129    family with seq sim 13 A1                            6                  4     0.0360
  FAM3C         7    120,776,141   family with sequence similarity 3 C                  6                  4     0.0109
  FAM3D         3    58,594,710    family with sequence similarity 3 D                  7                  4     0.0063
  FBXL17        5    107,223,348   F-box and leucine-rich repeat protein 17             6                  6     0.0430
  FGD2          6    37,081,401    FYVE, RhoGEF PH dom cont 2                           3                  4     0.0320
  FHIT          3    59,710,076    fragile histidine triad gene                         24                 62    0.0030
  FLJ11151      16   12,664,438    hypothetical protein FLJ11151                        4                  4     0.0380
  FLJ32682      13   45,013,433    hypothetical protein FLJ32682                        4                  5     0.0180
  FN1           2    215,933,422   fibronectin 1                                        3                  5     0.0260
  FOXP1         3    71,087,426    forkhead box P1                                      4                  17    0.0180
  FREM3         4    144,717,905   FRAS1 related extracellular matrix 3                 4                  6     0.0130
  FRMD4A        10   13,725,718    FERM domain containing 4A                            3                  23    0.0090
  GABBR2        9    100,090,187   GABA B receptor 2                                    11                 6     0.0073
  GLIS3         9    3,817,676     GLIS family zinc finger 3                            13                 18    0.0016
  GRB10         7    50,625,259    growth factor receptor-bound protein 10              3                  13    0.0083
  GRID1         10   87,349,292    delta 1 inotropic glutamate rec                      7                  18    0.0130
  GRIK1         21   29,831,125    kainate 1 inotropic glutamate rec                    4                  12    0.0150
  GTF2F2L       4    148,646,691   general transcription fact IIFpolypep 2-L            3                  3     0.0170
  HPSE2         10   100,208,867   heparanase 2                                         6                  18    0.0160
  HS3ST4        16   25,611,240    heparan sulfate 3-O-sulfotransferase 4               4                  11    0.0250
  IMPA2         18   11,971,455    inositol(myo)-1(or 4)-monophosphatase 2              6                  6     0.0064
  IQGAP2        5    75,734,905    IQ motif cont GTPase activ prot 2                    7                  5     0.0170
  JAKMIP1       4    6,106,385     janus kinase microtubule interacting protein 1       3                  8     0.0138
  KCNB1         20   47,421,912    Shab-rel volt-gated K chan 1                         5                  3     0.0190
  KCNIP4        4    20,339,337    Kv channel interacting protein 4                     13                 9     0.0107
  KCNJ6         21   37,918,655    inwardly-rect K chan J 6                             3                  8     0.0330
  KCNMA1        10   78,299,366    large conduct Ca-act K chan M α1                     8                  8     0.0390
  KIAA1576      16   76,379,984    KIAA1576 protein                                     3                  6     0.0260
  KREMEN1       22   27,799,106    kringle cont TM prot 1                               5                  4     0.0190
  KSR2          12   116,389,387   kinase suppressor of ras 2                           5                  4     0.0430
  LDLRAD3       11   35,922,188    low density lipoprotein recep cl A dom cont 3        3                  6     0.0330
  LTF           3    46,452,500    lactotransferrin                                     3                  4     0.0290
  MAGI1         3    65,314,946    membr-assoc G kinase WW PDZ dom cont 1               6                  9     0.0380
  MAGI2         7    77,484,310    membrane assoc G kinase WW PDZ dom 2                 9                  16    0.0430
  MGC23985      5    147,252,464   similar to AVLV472                                   3                  7     0.0085
  MICAL2        11   12,088,714    calponin LIM cont microtub monoxygenase 2            8                  8     0.0120
  MTSS1         8    125,632,212   metastasis suppressor 1                              9                  9     0.0050
  MTUS1         8    17,545,583    mitochondrial tumor suppressor 1                     3                  4     0.0090
  MYO18B        22   24,468,120    myosin XVIIIB                                        15                 8     0.0460
  MYO3A         10   26,263,202    myosin IIIA                                          3                  5     0.0018
  NAALADL2      3    176,059,805   N-Ac α-linked acidic dipeptidase-L 2                 4                  5     0.0340
  NFIA          1    61,320,881    nuclear factor I/A                                   4                  4     0.0080
  NLGN1         3    174,598,938   neuroligin 1                                         4                  4     0.0260
  OPCML         11   131,790,085   opioid binding protein/cell adhesion molecule-L      10                 13    0.0076
  PALM2         9    111,442,893   paralemmin 2                                         10                 16    0.0220
  PALM2-AKAP2   9    111,582,410   PALM2-AKAP2 protein                                  5                  10    0.0021
  PARD3B        2    205,118,761   par-3 partitioning defective 3 homolog B             3                  5     0.0160
  PDE4D         5    58,302,468    cAMP spec phosphodiesterase 4D                       4                  4     0.0140
  PKD1L2        16   79,691,991    polycystic kidney disease 1-like 2                   4                  4     0.0060
  PLD5          1    240,318,895   phospholipase D family 5                             3                  16    0.0300
  PRKCA         17   61,729,388    protein kinase C α                                   6                  4     0.0113
  PRKCH         14   60,858,268    protein kinase C η                                   7                  22    0.0300
  PRKG1         10   52,504,299    cGMP dep protein kinase I                            12                 10    0.0014
  PRPF4         9    115,077,795   PRP4 pre-mRNA process fact 4 homol                   6                  4     0.0360
  PSD3          8    18,432,343    pleckstrin and Sec7 domain containing 3              8                  16    0.0240
  PTPN14        1    212,597,634   no rec prot Y phosphatase 14                         10                 4     0.0150
  PTPRK         6    128,331,625   recept protein tyrosine phosphatase K                3                  8     0.0062
  PTPRT         20   40,134,806    recept prot Y phosphatase T                          3                  15    0.0190
  RBMS3         3    29,297,947    sing strand RNA binding motif interact prot          5                  13    0.0230
  ROR2          9    93,524,705    receptor tyrosine kinase-L orphan recept 2           5                  4     0.0290
  RORA          15   58,576,755    RAR-related orphan receptor A                        4                  9     0.0220
  SLC2A13       12   38,435,090    solute carrier family 2 13                           4                  4     0.0086
  SLIT3         5    168,025,857   slit homolog 3                                       3                  4     0.0370
  SRGAP3        3    8,997,278     SLIT-ROBO Rho GTPase activating protein 3            4                  23    0.0087
  STK32B        4    5,104,428     serine threonine kinase 32B                          3                  25    0.0011
  STK39         2    168,518,777   serine threonine kinase 39                           4                  4     0.0036
  SYNE1         6    152,484,516   spectrin rep cont nuclear envelope 1                 7                  5     0.0034
  TACC2         10   123,738,679   transforming acidic coil-coil cont prot 2            3                  9     0.0430
  TBC1D22A      22   45,537,213    TBC1 domain family 22A                               3                  8     0.0270
  TEK           9    27,099,286    TEK tyrosine kinase, endothelial                     3                  9     0.0420
  TG            8    133,948,387   thyroglobulin                                        4                  4     0.0180
  THSD4         15   69,220,842    thrombospondin I dom cont 4                          3                  11    0.0063
  TMEM132C      12   127,318,855   transmembrane protein 132C                           5                  13    0.0084
  TMEM132D      12   128,122,224   transmembrane protein 132D                           8                  11    0.0090
  TMEM16D       12   99,712,716    transmembrane protein 16D                            11                 11    0.0320
  TMTC1         12   29,545,024    transmemb tetratricopep rep cont 1                   3                  3     0.0035
  TRPC4         13   37,108,795    transient receptor potential cation channel C 4      8                  4     0.0140
  TULP4         6    158,653,680   tubby like protein 4                                 6                  9     0.0076
  UNC5C         4    96,308,712    unc-5 homolog C                                      9                  4     0.0162
  VAMP4         1    169,938,783   vesicle-associated membrane protein 4                3                  5     0.0170
  VAPB          20   56,397,651    vesicle-assoc memb protein-assoc prot B C            4                  11    0.0034
  VIT           2    36,777,418    Vitrin                                               3                  9     0.0110
  ZNF365        10   63,803,957    zinc finger protein 365                              6                  4     0.0340
  ZNF406        8    135,559,213   zinc finger protein 406                              16                 4     0.0014

The numbers of nominally-positive SNPs that lay in clusters within the gene\'s exons and in 10 kb genomic flanking regions are noted for each sample. Chromosome number and initial chromosomal position for the cluster (bp, NCBI Mapviewer Build 36.1) are listed. Nominal p values for each gene are based on 10,000 Monte Carlo simulation trials. For each trial, the number of times randomly-selected segments of the genome that lie within genes are assessed for the same features displayed by the actual gene identified. Note that the very highly significant p values for the overall convergence noted between these two datasets (text) does account for multiple comparisons, while the much more modest p values for many of the individual genes (displayed here) do not. Genes that are identified by clustered nominally positive SNPs in both samples but whose gene-wise p values lie \> 0.05 (perhaps, in part, due to the large size of the genes) include: C4orf13, PRKCE, UNC13C, KIAA1303, MYR8, DNAH11, ONECUT2, TGFBR3, TPD52L1, C9orf28, TMEM108, GALNT14, HECW2, NFIB, STS-1, KIAA1217, RAB3C, SNTG1, CPNE4, PTPRM, SLC39A11, MDS1, GPC5, ZNF533, NR5A2, RYR3, C8orf68, CTNNA2, GRM5, ATRNL1, ARL15, BTBD9, CNTNAP5, GALNTL4, PELI2, SNRPN, GPR98, ERC2, NFATC2, FLJ16124, GRM7, SORCS2, NPAS3, PARVB, IGL@ and LRP1B.

We would anticipate the observed, highly-significant clustering of SNPs that display nominally-positive results if many of these reproducibly-positive SNPs lay near and were in linkage disequilibrium with functional allelic variants that distinguished substance-dependent subjects from control subjects. We would not anticipate this degree of clustering if the results were solely due to chance. The Monte Carlo p values noted here are thus likely to receive contributions from both the extent of linkage disequilibrium among the clustered, nominally-positive SNPs and the extent of linkage disequilibrium between these SNPs and the functional haplotype(s) that lead to the association with substance dependence.

Neither controls for occult stratification nor for assay variability appear to provide convincing alternative explanations for most of the data obtained here. When we examined the overlap between the 7620 clustered positive SNPs from the ECA samples and: 1) the 2.5% of the SNPs for which the noise in validating studies was highest and 2) the 2.5% of SNPs that displayed the largest differences between Baltimore African-American *vs*European American control individuals, we found 15 and 245, respectively, *vs*185 expected by chance in each case.

We evaluated evidence for preferential brain and brain regional expression of the 172 genes identified in Table [1](#T1){ref-type="table"} (body and legend). Brain libraries represented in dbEST contained ESTs that corresponded to 91% (157/172) of these genes. Expression for this set of genes (*compared to all genes*) displayed nominal significance in thalamus (p \< 10^-8^), amygdale (p = 5.6 × 10^-9^), hippocampus (p = 2.6 × 10^-5^), frontal cortex (p = 0.015) and medulla (p = 0.039) using hypergeometric tests (p values were Bonferroni corrected for repeated comparisons). Assessments of the \"more reliable\" subset of ESTs revealed significant overexpression in whole brain (p = 2.1 × 10^-7^), amygdala (p = 4.4 × 10^-6^), hippocampus (p = 0.0011), cerebellum (p = 0.0052), thalamus (p = 0.037) and cortex (p = 0.049) (p-values were Bonferroni corrected).

Discussion
==========

The current results 1) provide independent support for GWA results from larger samples of research volunteers studied for substance dependence phenotypes and 2) provide a control for one of the potential confounding features of this previously-studied sample. The possibility that genetic results from members of any sample of research volunteers might not represent the genetics of members of the general population is ever present. In molecular genetic studies of substance dependence, however, features that are both 1) heritable and 2) differentially present in substance dependent individuals might, *a priori*, be considered to be especially likely to provide confounding influences. Cognitive abilities are highly heritable. Cognitive tests in a number of samples of substance dependent individuals have indicated differences in performance (reviewed in \[[@B13]\]). A study in twin pairs whose members were discordant for substance use concluded that most of these cognitive differences were likely to be heritable antecedents to, not just consequences of, the use of addictive substances \[[@B37]\]. Cognitive abilities have been shown to interact with willingness to volunteer for and/or participate in research protocols in a number of settings \[[@B1],[@B12],[@B14]-[@B25]\]. A number of personality features are also highly heritable \[[@B38]\]. Neuroticism is both one of the more heritable personality features and also the personality feature that has been demonstrated to be elevated in several samples of substance dependent individuals \[[@B38]\]. Personality features have also been linked to willingness to volunteer for participation in research protocols \[[@B1],[@B12],[@B14]-[@B25]\]. A number of psychiatric disorders that might also be linked to differential willingness (or ability) to participate as a research volunteer are also heritable and co-occur with substance dependences at rates much greater than chance \[[@B13]\].

It is also important to keep a number of limitations in mind in considering the present results. 1) The preplanned approach used here demands that multiple nominally-positive SNPs from each sample tag the same genomic region that lies within a gene. Requirements that nominally positive SNPs from the current dataset come from each of the two 500 k array types add a technical control. Monte Carlo approaches that do not require specification of underlying distributions can readily judge the degree to which all of the observations made here could be due to chance. Nevertheless, there have been no unanimous criteria for declaring \"replication\" or \"convergence\" for GWA studies, a consideration worth considering in evaluating the current results. 2) The ECA samples are of modest size, limited by the numbers of substance abusing or dependent individuals in the aging Baltimore ECA cohort follow-up samples. Power calculations that document the modest power in European-Americans samples revealed even more modest power for the smaller number of African-American substance dependent individuals in this sample; we have thus not analyzed these samples. Modest power limits interpretation of negative data, substantially restricting inferences about genes identified in the more robust dataset from MNB research volunteers but not in these ECA samples. 3) There is very highly significant confidence in the overall set of convergent positive results reported here. However, the values for each gene, tested individually, provide much more modest levels of statistical assurance. 4) Focus on data from autosomes here allows us to combine data from male and female subjects, but misses potentially important contributions from sex chromosomes. 5) The individuals in the Baltimore ECA cohort were not initially sampled based on their willingness to be volunteers. However, participants needed to consent in order to be able to be followed and studied genetically. Although the overwhelming majority of the European-American participants who were followed did consent to participation in genetic studies, potential contributions that the non-consenting individuals might have made to the present results remain unknown. 6) The pooling approach that we use here provides excellent correlations between individually-genotyped and pooled allele frequency assessments in validation experiments. This approach has allowed us to use these samples without adding additional confidentiality burdens to these intensively-studied individuals. Nevertheless, estimates of allele frequencies based on pooled data represent approximations of \"true\" allele frequency differences that might be determined by error free individual genotyping of each participant. 7) There is no indication that the overall positive results reported here are based on the SNPs whose assays provide more noise, and no indication that occult stratification on racial/ethnic lines contributed overall to the results that we obtain here. However, we cannot totally exclude contributions of occult stratification that cannot be detected by these overall screens to findings in specific genes. 8) The convergent data derived from studies of individuals with dependence on substances in several different pharmacological classes supports the idea that many allelic variants enhance vulnerability to dependence on a number of substances. These results do not exclude additional contributions from genomic variants that influence vulnerability to specific substances. 9) We focus on identification of genes. Although associations away from annotated genes can also provide interesting results, the genes that we identify in the present work provide a number of interesting views of substance dependence. These data reinforce our observations that many of these genes are likely to contribute to brain differences that are reflected in the mnemonic aspects of addiction, and that some of them also provide tempting targets for antiaddiction therapeutics. We discuss these ideas in more detail elsewhere \[[@B12],[@B13]\].

More of the genes identified here are represented among cDNAs cloned from brain libraries than is the case for all human genes. The results focus attention on expression in hippocampus, which manifests interesting roles in mnemonic processes and cerebral cortical connections that may provide additional clues to the pathophysiology of human substance dependence. Although detailed discussion of each of these groups of genes is beyond the scope of this report, it is interesting to note that about 15% of the genes enumerated in Table [1](#T1){ref-type="table"} can be related to cell adhesion mechanisms. This is a much larger fraction that the fraction of all genes, about 2%, that are identified as cell adhesion molecules in a recent bioinformatic approach to comprehensively identifying cell adhesion molecules \[[@B39]\], supporting overrepresentation of these genes among addiction-associated genes.

A number of the genes identified in this work are also identified in genome wide association and/or candidate gene datasets for heritable disorders or phenotypes that co-occur with addictions. As we discuss elsewhere, dependence-vulnerability GWA results overlap at levels greater than expected by chance with GWA studies of cognitive abilities, personality features, frontal lobe brain volumes and bipolar disorder \[[@B13]\].

Conclusion
==========

The observations in the present dataset that the findings from a population-based sample converge strongly with those made in larger research volunteer samples are reassuring. They support the idea that many of the molecular genetic findings that we and others have previously reported are not due simply to the methods used for ascertainment of \"cases\" and \"controls\" for our studies in research volunteers. It is important to note that this overall conclusion does not exclude contributions for some of these sampling issues to findings in particular genes. Nevertheless, the findings presented here promise to add to ongoing processes for comparing GWA datasets from research volunteers to those from population based samples. For dependence on alcohol, tobacco and other drugs, as for many complex disorders, such data provides an increasingly rich basis for improved understanding and for personalization of prevention and treatment strategies.
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